Skip to content

13F-HR filed by Consonance Capital Management LP

Consonance Capital Management LP filed this 13F-HR for the quarter ended 2019-09-30, filed 2019-11-14, with 30 holding rows worth $1,010,567,000.

Accession
0001085146-19-002949
Filed
2019-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2019

A holdings report, 30 entries on the cover page, a total value of $1,010,567,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,010,567,000 with VALUE read as thousands by filing date, 13F file number 028-14924. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AMARIN CORP PLC023111206SPONS ADR NEW6,390,259$96,876,000thousands by filing date
CATALYST PHARMACEUTICALS INC14888U101COM17,875,655$94,920,000thousands by filing date
UNITED THERAPEUTICS CORP DEL COM91307C102Stock967,569$77,164,000thousands by filing date
GLOBUS MED INC CL A379577208Stock1,313,177$67,130,000thousands by filing date
TANDEM DIABETES CARE INC875372203COM NEW1,022,257$60,293,000thousands by filing date
UNIQURE NVN90064101SHS1,428,202$56,214,000thousands by filing date
KARYOPHARM THERAPEUTICS INC48576U106COM5,837,434$56,156,000thousands by filing date
VERICEL CORP92346J108COM3,644,492$55,178,000thousands by filing date
ALIGN TECHNOLOGY INC COM016255101Stock299,000$54,095,000thousands by filing date
OMEROS CORP682143102COM2,831,109$46,232,000thousands by filing date
EPIZYME INC29428V104COM3,975,054$41,003,000thousands by filing date
OXFORD IMMUNOTEC GLOBAL PLCG6855A103ORD SHS2,144,524$35,663,000thousands by filing date
STAAR SURGICAL CO COM PAR $0.01852312305Stock1,227,771$31,652,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM1,679,327$30,564,000thousands by filing date
ARQULE INC04269E107COM4,011,342$28,761,000thousands by filing date
KADMON HLDGS INC48283N106COM10,693,574$26,948,000thousands by filing date
RETROPHIN INC761299106COM2,314,421$26,824,000thousands by filing date
INSULET CORP COM45784P101Stock155,800$25,696,000thousands by filing date
ADMA BIOLOGICS INC000899104COM5,114,986$22,762,000thousands by filing date
CAREDX INC14167L103COM726,128$16,418,000thousands by filing date
AURINIA PHARMACEUTICALS INC COM05156V102Stock2,561,269$13,677,000thousands by filing date
CHEMOCENTRYX INC16383L106COM1,666,667$11,300,000thousands by filing date
ANI PHARMACEUTICALS INC00182C103COM142,943$10,418,000thousands by filing date
MUSTANG BIO INC62818Q104COM3,160,000$10,302,000thousands by filing date
KRYSTAL BIOTECH INC COM501147102Stock224,090$7,782,000thousands by filing date
SAVARA INC805111101COM1,568,002$4,155,000thousands by filing date
SAREPTA THERAPEUTICS INC803607100COM12,000$904,000thousands by filing date
TRANSPORTATION & LOGISTI438083107COM40,557$734,000thousands by filing date
IMMUNOMEDICS INC452907108COM45,000$597,000thousands by filing date
INTRA-CELLULAR THERAPIES INC46116X101COMMON STOCK20,000$149,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001085146-19-002949this filing2019-11-14acceptance time not in the bulk data set